Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 807-812

  Crivellari, D ^a   Lombardi, D ^a   Corona, G ^a   Massacesi, C ^b   Talamini, R ^a   Sorio, R ^a   Magri, M D ^a   Lestuzzi, C ^a   Lucenti, A ^c   Veronesi, A ^a   Toffoli, G ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

^c General Hospital   (Italy)

Author keywords

Elderly breast cancer patients; Oral idarubicin

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IDARUBICINOL;

ACUTE HEART INFARCTION; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG MONITORING; DRUG TOLERABILITY; ELDERLY CARE; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; IDARUBICIN; LIVER NEOPLASMS; LUNG NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 33646202671     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl013     Document Type: Article

References (40)

1. Harris JR, Morrow M, Norton L. Malignant tumors of the breast. In: Cancer Principles and Practice of Oncology 5th Edn. De Vita V et al. (eds). Philadelphia, PA: Lippincott 1997; 1557-1616.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Di Marco A, Casazza AM, Pratesi G. Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 1977; 61: 893-895.
4. Fields SM, Koeller JM. Idarubicin: A second-generation anthracycline. Ann Pharmacol 1991; 25:505-517.
5. Cersosimo RJ. Idarubicin: An anthracycline antineoplastic agent. Clin Pharm 1992; 2: 152-167.
6. Howard MR, Taylor PRA, Proctor SJ. Oral idarubicin in hematological malignancy: Current trends in therapy. Clin Drug Invest 1995; 9: 16-28.
7. Keating MJ. Oral idarubicin in hematological malignancies: Putative indications. Clin Drug Invest 1995; 9: 29-38.
8. Twelves CJ. Oral idarubicin in solid tumor chemotherapy. Clinical Drug Investigation 1995; 9: 39-54.
9. Lasota WS, De Valeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs and Ageing 1994; 4(5): 392-402.
10. Toffoli G, Sorio R, Aita P et al. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Canc Res 2000; 6: 2279-2287.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Toffoli G, Corona G, Simone F et al. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines. Int J Cancer 1996; 67: 129-137.
13. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics 1999; 55: 484-487.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 456-481.
15. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd edn. Oxford: Blackwell Scientific 1994: 386-401.
16. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
17. Hortobagyi GN, Frye D Buzdar AU et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37-45.
18. Lipshultz SE, Giantris AL, Lipsitz SR et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002; 20: 1677-1682.
19. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
20. Gross CP, Herrin J, Wong N. et al: Enrolling older persons in cancer trials: The effect of sociodemographic, protocol, and recruitment centre characteristics. J Clin Oncol 2005; 23: 4755-4763.
21. Martoni A, Pacciarini MA, Pannuti F. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 803-806.
22. Lionetto R, Pronzato P, Conte PF et al. Idarubicin in advanced breast cancer: A phase II study. Cancer Treat Rep 1986; 70: 1439-1440.
23. Kolaric K, Mechl Z, Potrebica V, Sopkova B. Phase II study of oral 4-demethoxydaunorubicin in previously treated metastatic breast cancer. Oncology 1987; 44: 82-86.
24. Casper ES, Raymond V, Hakes TB et al. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer. Cancer Treat Rep 1987; 71(12):1289-1290.
25. Bastholt L, Dalmark M. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep 1987; 71: 451-454.
26. Chevallier B, Monnier A, Metz R et al. Phase II study of oral idarubicin in elderly patients with advanced breast cancer. Am J Clin Oncol (CCT) 1990; 13(5): 436-439.
27. Stuart NSA, Cullen MH, Priestman TJ et al. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. Cancer Chemother Pharmacol 1988; 21: 351-354.
28. Hurteloup P, Armand JP, Schneider M et al. Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The clinical screening group of the European Organization for Research and Treatment of Cancer. Eur J Cancer Clin Oncol 1989; 25(3): 423-428.
29. Possinger K, Wagner H, Worst P et al. Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. Onkologie 1991; 14: 31-34.
30. Wander HE, Meyer D, Schuff-Werner P, Nagel GA. Phase II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer (ABC). Onkologie 1986; 9: 236-238.
31. De Lena M, Brandi M, Bozzi D et al. 4-demethoxydaunorubicin administered orally in advanced breast cancer A phase II study. Tumori 1988; 74: 65-70.
32. Lopez M, Di Lauro L, Papaldo P et al. Phase II trial with oral idarubicin in advanced breast cancer. Investigational New Drugs 1986; 4: 39-42.
33. Lopez M, Contegiacomo A, Vici P et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64: 2431-2436.
34. Piccart MJ, De Valeriola D, Tomiak E. Anthracyclines active via the oral route: Luxury or necessity? Ann Oncol 1992; 3: 181-182.
35. Greco FA. Chronic etoposide administration: Overview of clinical experience. Cancer Treat Rev 1993; 19(C): 35-45.
36. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-432.
37. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 1-7.
38. Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16: 253-258.
39. Feher O, Vodvarka P, Jassem J et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomised, phase III study. Ann Oncol 2005; 16: 899-908.
40. Camidge R, Reigner B, Cassidy J et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005; 23: 4719-4725.